Welcome to our dedicated page for BIOTRICITY news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on BIOTRICITY stock.
Biotricity, Inc. (BTCY) is a medical technology company at the forefront of healthcare innovation. Specializing in biometric data monitoring solutions, Biotricity aims to improve healthcare by developing remote monitoring solutions for chronic disease prevention and management. Its premier product, Bioflux, is an ECG monitoring system used by physicians to diagnose and monitor cardiac patients remotely. Biotricity's Biolife solution extends medical-grade monitoring to the consumer market, empowering users to self-manage chronic conditions through lifestyle changes. With a focus on preventive healthcare, Biotricity's R&D efforts aim to put health management directly into the hands of individuals, easing the burden on the healthcare system.
Biotricity Inc. (NASDAQ:BTCY) has launched its Bioheart heart monitor system on Amazon.com, enhancing consumer access to advanced cardiac monitoring without a prescription. Priced at $199, the device is available for a limited introductory price of $149. The Bioheart offers continuous 24/7 data collection, advanced analytics, and innovative features like retrospective snapshots of heart data. This expansion not only opens new revenue streams for Biotricity but also targets a $1.24B market. The product aims to transform cardiac health monitoring through a virtual cardiac clinic ecosystem.
Biotricity Inc. (NASDAQ:BTCY) has successfully completed a $12 million non-convertible debt financing with SWK Funding LLC to replace existing debt and support inventory and annual recurring revenue (ARR) subscriptions. The financing includes a five-year term with an interest-only period of two years, leading to a 40% balloon payment at maturity. This capital infusion strengthens Biotricity's balance sheet without diluting equity shareholders and positions the company for upcoming product launches in 2022.
Biotricity (NASDAQ:BTCY) has released its December 2021 CEO Shareholder Letter, outlining key milestones and growth strategies for 2022. The Company reports a record quarterly revenue of $1.81 million, representing a 143% year-over-year increase. Significant achievements include its recent uplisting to Nasdaq, aimed at attracting institutional investors and enhancing liquidity. The shareholder letter highlights the successful commercialization of the Biokit and outlines future goals, including the launch of innovative cardiac monitoring solutions.
Biotricity (NASDAQ:BTCY) has launched Bioheart, an innovative heart monitor that allows users to access continuous heart monitoring technology directly via a smartphone app. Bioheart targets a growing market valued at
Biotricity Inc. (NASDAQ:BTCY) reported its tenth consecutive quarter with triple-digit year-over-year revenue growth, achieving $1.81 million in Q2-FY22, a 143% increase compared to the prior year. The company incurred a net loss of $11 million, primarily due to $5.46 million in one-time expenses linked to its Nasdaq up-listing. Biotricity's balance sheet is robust, with $11.7 million in cash. The company introduced Biokit, a home-use cardiac monitoring device anticipated to launch in early 2022, indicating a strong product pipeline aimed at improving patient outcomes.
Biotricity, Inc. (BTCY) has announced the release of its financial results for the second quarter, ending September 30, 2021, scheduled for November 4, 2021, after market close. The company will host a conference call and live webcast at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. Biotricity focuses on remote health monitoring solutions, aiming to enhance preventive and personal care for chronic conditions.
Biotricity, Inc. (NASDAQ:BTCY) will present at the Virtual LD Micro Main Event XIV on October 13, 2021, at 5:00 PM PT. CEO Waqaas Al Siddiq will discuss recent milestones, including the development of Biokit, a home-use health monitoring solution, and the Biocare Cardiac app for cardiovascular health. The event, a key convention for small-cap companies, aims to connect industry leaders with analysts and investors. Biotricity focuses on innovative remote health monitoring solutions, aiming to improve chronic care management.
Biotricity Inc. (NASDAQ:BTCY) announced the launch of Biocare Cardiac, a cardiac health app designed for individuals with cardiovascular disease, compatible with Samsung's Galaxy Watch4. This app enables continuous monitoring of heart health, collecting data on ECG, heart rate, and more, facilitating better patient-doctor interactions. Biotricity aims to empower cardiac patients by providing tools for daily health management, addressing a significant gap in cardiac care. The app complements Biotricity's existing healthcare solutions, reinforcing its position in remote monitoring.
Biotricity Inc. (NASDAQ:BTCY) will ring the Nasdaq Opening Bell on October 7, 2021, at 9:30 AM ET. The ceremony will be attended by Founder and CEO Waqaas Al Siddiq and the management team. Recent developments include a financing initiative to support sales expansion while minimizing dilution and maximizing shareholder value. Additionally, Biotricity has expanded its telehealth product portfolio, enhancing its market potential. The event can be viewed on the Nasdaq live stream, with a replay available on the company's investor relations website.
Biotricity Inc. (NASDAQ:BTCY) announced its CEO, Waqaas Al Siddiq, will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 12:15 p.m. ET. The presentation will cover the company's strategic outlook for 2022, recent developments, and new products, including the Biokit bundle of wireless cardiac data devices. Biotricity aims to expand its market share and enhance shareholder value through its technology leadership and product pipeline. A replay of the presentation will be accessible on the corporate website for 30 days.
FAQ
What is the current stock price of BIOTRICITY (BTCY)?
What is the market cap of BIOTRICITY (BTCY)?
What is Biotricity, Inc.?
What are some of Biotricity's products?
What is the vision of Biotricity, Inc.?
How does Biotricity contribute to the healthcare industry?
